Menopur

Menotropin, the active ingredient in Menopur, is a gonadotropin presented as a powder for solution for injection for subcutaneous use. It stimulates follicular development and ovulation in women undergoing assisted reproductive technology, anovulatory patients, and those with hypogonadotropic hypogonadism.

GNH USA supplies Menopur as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menotropin (Menopur) is used in the reproductive endocrine pathway to support follicular growth and ovulation. - Ovarian stimulation for assisted reproductive technology (ART): enhances follicle development to increase the number of retrievable oocytes. - Induction of ovulation in anovulatory women: promotes ovulation in patients with conditions such as polycystic ovary syndrome. - Treatment of hypogonadotropic hypogonadism: provides necessary FSH and LH activity to stimulate gonadal function in patients with deficient gonadotropin secretion.

Menotropin may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Ovarian hyperstimulation syndrome (mild): abdominal bloating, nausea, mild weight gain. - Headache: transient headache. - Nausea: occasional nausea.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, ascites, thromboembolism. - Multiple pregnancy: increased risk of twins or higher‑order gestations. - Allergic reaction: rash, urticaria, anaphylaxis.

When using Menotropin, clinicians should observe specific safety measures. - Patient selection: assess ovarian reserve and risk factors for OHSS before initiating therapy. - Monitoring: perform regular ultrasound and estradiol measurements to adjust dose. - Contraindications: avoid in active ovarian cysts, uncontrolled thyroid disease, or estrogen‑dependent tumors. - Pregnancy: discontinue once pregnancy is confirmed. - Thromboembolic risk: monitor for signs of blood clots in high‑risk patients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menotropin can interact with other agents that affect hormonal balance or clotting.

Major Interactions (Avoid): - GnRH agonists/antagonists: may alter response and increase OHSS risk. - Hormonal contraceptives: can suppress endogenous gonadotropin response, reducing efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of thrombosis with OHSS. - Thyroid hormone therapy: may require dose adjustments. - Steroids: may affect ovarian response.